Viking TherapeuticsLTS:0VQA +6.74%29 FCF Yield % is -6.96 as of Jul. 08, 2026. GuruFocus rates LTS:0VQA with a GF Score™ of 29/100. The stock has 3 warning signs investors should review. Among 1,406 Biotechnology companies, Viking Therapeutics ranks better than 55.9% on this metric.
FCF Yield % is calculated as Free Cash Flow divided by Market Capitalization. It is a financial solvency ratio that compares the free cash flow a company is expected to earn against its market value.
Similar to Earnings Yield %, FCF Yield % is financial solvency ratio. A lower ratio suggests a less attractive investment, indicating that investors might not receive substantial returns in proportion to their investment. Conversely, a high free cash flow yield signals that a company generates sufficient cash to comfortably meet its debts, obligations, and dividend payments, making it a promising investment choice.
Viking Therapeutics FCF Yield % Related Terms
Viking Therapeutics FCF Yield % Historical Data
* Premium members only.
The historical data trend for Viking Therapeutics's FCF Yield % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
LTS:0VQA vs EWTX, ACAD, DNLI: FCF Yield % Comparison
For the Biotechnology subindustry, Viking Therapeutics's FCF Yield %, along with its competitors' market caps and FCF Yield % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Viking Therapeutics FCF Yield % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Viking Therapeutics's FCF Yield % distribution charts can be found below:
* The bar in red indicates where Viking Therapeutics's FCF Yield % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Viking Therapeutics (LTS:0VQA) has a FCF Yield % of -6.96 as of Jul. 08, 2026. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Viking Therapeutics and its competitors. According to the industry distribution chart, Viking Therapeutics ranks #620 out of 1406 companies in the Biotechnology industry, placing it in the top 44.1%.
Is Viking Therapeutics' FCF Yield % too high?
Viking Therapeutics' current FCF Yield % is -6.96. Based on the distribution chart, Viking Therapeutics ranks #620 out of 1406 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Viking Therapeutics has a GF Score™ of 29/100, reflecting its overall financial health beyond just this single metric.
How does Viking Therapeutics' FCF Yield % compare to EWTX and ACAD?
According to the Biotechnology industry distribution chart, Viking Therapeutics ranks #620 out of 1406 companies for FCF Yield %. This puts Viking Therapeutics in the upper half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Yield % for a Biotechnology company?
A good FCF Yield % depends on the Biotechnology industry context. However, FCF Yield % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Yield % mean?
A high FCF Yield % can signal that a stock is expensive relative to its fundamentals. FCF Yield is calculated as Free Cash Flow divided by Market Capitalization. View historical data on Viking Therapeutics and its competitors. Viking Therapeutics's current FCF Yield % is -6.96. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Viking Therapeutics stock overvalued right now?
Viking Therapeutics (LTS:0VQA) has a current FCF Yield % of -6.96. The current FCF Yield % is -6.96. Viking Therapeutics' overall GF Score™ is 29/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Yield % calculated?
FCF Yield % is calculated from a company's financial statements. For Viking Therapeutics (LTS:0VQA), the current FCF Yield % is -6.96 as of Jul. 08, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Viking Therapeutics Inc is a healthcare service provider. The company specializes in the area of biopharmaceutical development focused on metabolic and endocrine disorders. The company's clinical program pipeline consists of VK2809, VK5211, and VK0214 products. VK2809 and VK0214 are orally available, tissue and receptor-subtype-selective agonists of the thyroid hormone receptor beta. VK5211 is an orally available, non-steroidal selective androgen receptor modulator.
29GF Score
Get the complete analysis for LTS:0VQA
FCF Yield % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
LTS:0VQA has been successfully added to your 
